Suchergebnisse - "Spiekermann, Karsten"

PubPharm (17)

1

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

ErratumIn: Cancer Immunol Immunother. 2023 May 8;:. - PMID 37154851

2

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

3

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

4

CD33 $ BiTE^{®} $ molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

enthalten in: Cancer immunology immunotherapy | 2023

von Marcinek, A. | Brauchle, B. | Rohrbacher, L. | +13

5

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

enthalten in: Annals of hematology | 2023

von Berdel, A. | Koch, R. | Gerss, J. | +15

6

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

enthalten in: Annals of hematology | 2022

von Berdel, A. | Koch, R. | Gerss, J. | +15

7

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

enthalten in: Annals of hematology | 2022

von Berdel, A. | Koch, R. | Gerss, J. | +15

8

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

enthalten in: Journal of hematology & oncology | 2022

von Kunadt, D. | Stasik, S. | Metzeler, K. | +44

9

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

enthalten in: Journal of hematology & oncology | 2022

von Kunadt, D. | Stasik, S. | Metzeler, K. | +43

10

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

enthalten in: European journal of medicinal chemistry | 2020

von Sellmer, A. | Pilsl, B. | Beyer, M. | +13